When was ExocoBio founded?

ExocoBio was founded in 2017 and raised its 1st funding round within a year of its incorporation.

Where is ExocoBio located?

ExocoBio is headquartered in Seoul, South Korea.

Who is the current CEO of ExocoBio?

Byong Seung Cho of ExocoBio. They have also founded 1 company.

How many employees does ExocoBio have?

As of Jun 30, 2026, the latest employee count at ExocoBio is 28.

Is ExocoBio a funded company?

ExocoBio is a funded company, having raised a total of $47.3M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on May 02, 2017.

When was the latest funding round of ExocoBio?

ExocoBio's latest funding was a $***** Series C round on Aug 25, 2020, with participation from 4 investors. Its primary sector is Dermatology. In South Korea, the Dermatology sector has seen $17M in funding in 2026 to date.

Where does ExocoBio rank among its competitors?

ExocoBio ranks 3rd amongst 16 active competitors, of which 4 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was PranaX, which secured $17M in Jan, 2026.

Who are the top competitors of ExocoBio?

ExocoBio's top competitors include PranaX, ELEVAI Labs and Pia. Among them, PranaX secured the most recent funding round in January, 2026.

ExocoBio - 2026 Company Profile, Team, Funding & Competitors

Company Details

ExocoBio has developed an exosome-based therapeutics for regenerative medicine. The therapy uses exosomes secreted by stem cells which stimulate cellular regeneration. The stem cell-derived exosomes contain growth factors and are involved in cell-to-cell communication. The ASC-Exosome has been developed for skin regeneration. The company is developing exosome-based cosmeceuticals, medical devices, skin & hair regeneration and biopharmaceuticals.

Website: exocobio.com
Social

Key Metrics

Founded Year

2017

Location

Seoul, South Korea

Stage

Series C

Total Funding

$47.3M in 3 rounds

Latest Funding Round

Series C, Aug 25, 2020, $*****

Investors

Atinum Investment & 17 more

Ranked

3^rd among 16 active competitors

Employee Count

28 as on Jun 30, 2026

Similar Companies

PranaX & 15 more

View ExocoBio's full profile

ExocoBio has raised a total funding of $47.3M over 3 rounds. Its first funding round was on May 02, 2017. Its latest funding round was a Series C round on Aug 25, 2020 for $*****. 4 investors participated in its latest round. ExocoBio has 18 institutional investors.

Here is the list of recent funding rounds of ExocoBio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 25, 2020	7893400	Series C	8850447	4800927	7173313	6077962
Sep 12, 2018	8386714	Series B	6451599	8356185	5487436	8120918
May 02, 2017	7167606	Series A	6517503	8729944	ID Ventures & 3 more	2648953

Access funding benchmarks and valuations. Sign up today!

View details of ExocoBio's funding rounds and investors

The founders of ExocoBio is Byong Seung Cho. Byong Seung Cho is the CEO of ExocoBio.

Here are the details of ExocoBio's key team members:

Byong Seung Cho: Co-Founder & CEO of ExocoBio.
Contact Info: 1 email address

View details of ExocoBio's Founder profiles and Board Members

ExocoBio's employee count trend

ExocoBio has 28 employees as of Jun 26. Here is ExocoBio's employee count trend over the years:

Uncover ExocoBio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ExocoBio include PranaX, ELEVAI Labs and Pia. Here is the list of Top 10 competitors of ExocoBio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	PranaX 2022, Houston (United States), Series A	Provider of regenerative science to treat various health conditions	$27M	-	56/100
2nd	ELEVAI Labs 2020, California City (United States), Public	Developer of regenerative aesthetic dermatology products	-	-	47/100
3rd	ExocoBio 2017, Seoul (South Korea), Series C	Developer of exosome-based therapeutics for regenerative medicine	$47.3M	DT&Investment, GNTech Venture Capital & 16 others	44/100
4th	Pia 2011, Shinagawa (Japan), Unfunded	Developer of stem cell-derived exosomes for dermatological conditions	-	-	38/100
5th	Aegle Therapeutics 2013, Miami (United States), Series A	Developing extracellular vesicle therapies for debilitating rare diseases and dermatological disorders	$6.5M	New World Angels, Springboard Enterprises ... & 7 others	37/100
6th	Exotropin 2023, New York (United States), Unfunded	Developer of exosome-based health and beauty products	-	-	32/100
7th	NextPhase Therapeutics 2020, Seattle (United States), Unfunded	Developer of topical therapeutics for dermatological diseases	-	-	30/100
8th	Brexogen 2019, Seoul (South Korea), Funding Raised	Developer of exosome therapies for various conditions	-	Korea Investment Holdings, UTC Investment	28/100
9th	EXO Biologics 2019, Niel (Belgium), Series A	Developer of cell-based therapeutics	$17.1M	Noshaq	26/100
10th	Curexsys 2020, Gottingen (Germany), Unfunded	Developer of therapeutics to treat age-related diseases	-	-	26/100